Author Archives: Chandra Ganegoda

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+(TM) for Prostate Cancer

Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer Immune stimulating components of ...

BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University ...

BriaCell Phase 3 Bria-IMT(TM) Study Enrollment Surpasses 230 Patients

Over 315 patients screened and over 230 patients enrolled in BriaCell’s pivotal Phase 3 Bria-ABC ...

BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Receives FDA Clearance to Initiate Bria-BRES+(TM) Clinical Study in Breast Cancer

FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical ...

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient

IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic ...

Eleven clinical trials that will shape medicine in 2026″ – BriaCell Phase 3 Trial Featured in Nature Medicine

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited ...

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium ...